The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Extended neoadjuvant chemotherapy (CT) in borderline resectable pancreas cancer (BRPC).
J Bart Rose
No relevant relationships to disclose
Flavio G. Rocha
No relevant relationships to disclose
Bruce S. Lin
No relevant relationships to disclose
Adnan Alseidi
No relevant relationships to disclose
Thomas A. Biehl
No relevant relationships to disclose
Ravi Moonka
No relevant relationships to disclose
John A. Ryan
No relevant relationships to disclose
L. William Traverso
No relevant relationships to disclose
Scott Helton
No relevant relationships to disclose
Vincent J. Picozzi
Stock Ownership - Amgen
Research Funding - Aduro Biotech; Clovis; FibroGen; Immunomedics; Theranostics Health